Business News • PR NewsWire • CTI BioPharma and Baxter Announce Phase 3 Data of Pacritinib in Patients with Myelofibrosis to be Presented in Late-Breaking Session at ASCO

CTI BioPharma and Baxter Announce Phase 3 Data of Pacritinib in Patients with Myelofibrosis to be Presented in Late-Breaking Session at ASCO

CTI BioPharma and Baxter Announce Phase 3 Data of Pacritinib in Patients with Myelofibrosis to be Presented in Late-Breaking Session at ASCO

SEATTLE and DEERFIELD, Ill., April 22, 2015 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) and Baxter International Inc. (NYSE:BAX) today announced that data from the randomized Phase 3 PERSIST-1 trial evaluating the investigational agent pacritinib in...

View More : http://www.prnewswire.com/news-releases/cti-biopharma-and-baxter-announce-phase-3-data-of-pacritinib-in-patients-with-my...

Releted News by prnewswire

Elekta to highlight Elekta Radiosurgery Solutions, Information-guided cancer care at 3rd ESTRO Forum

CYBIRD's "Midnight Cinderella: Ikemen Royal Romances," Most Popular Title's English Version in "Ikemen Series" Now Available at Amazon Appstore